Advertisement

Table of Contents

February 01, 1996; Volume 49,Issue 2

You have access
RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification.
A P Ford, N F Arredondo, D R Blue, D W Bonhaus, J Jasper, M S Kava, J Lesnick, J R Pfister, I A Shieh, R L Vimont, T J Williams, J E McNeal, T A Stamey and D E Clarke

Molecular Pharmacology February 1996, 49 (2) 209-215;
You have access
The conserved aspartate residue in the third putative transmembrane domain of the delta-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site.
K Befort, L Tabbara, S Bausch, C Chavkin, C Evans and B Kieffer

Molecular Pharmacology February 1996, 49 (2) 216-223;
You have access
Expression cloning of a human brain neuropeptide Y Y2 receptor.
D R Gehlert, L S Beavers, D Johnson, S L Gackenheimer, D A Schober and R A Gadski

Molecular Pharmacology February 1996, 49 (2) 224-228;
You have access
Proteinase-activated receptor-2 in rat aorta: structural requirements for agonist activity of receptor-activating peptides.
M D Hollenberg, M Saifeddine and B al-Ani

Molecular Pharmacology February 1996, 49 (2) 229-233;
You have access
Epitope mapping studies with human anti-cytochrome P450 3A antibodies.
J S Leeder, A Gaedigk, X Lu and V A Cook

Molecular Pharmacology February 1996, 49 (2) 234-243;
You have access
Genesis of discrete higher order DNA fragments in apoptotic human prostatic carcinoma cells.
J M Rusnak, T P Calmels, D G Hoyt, Y Kondo, J C Yalowich and J S Lazo

Molecular Pharmacology February 1996, 49 (2) 244-252;
You have access
Cloning of cDNAs encoding the human gamma-aminobutyric acid type A receptor alpha 6 subunit and characterization of the pharmacology of alpha 6-containing receptors.
K L Hadingham, E M Garrett, K A Wafford, C Bain, R P Heavens, D J Sirinathsinghji and P J Whiting

Molecular Pharmacology February 1996, 49 (2) 253-259;
You have access
Expression, induction, and catalytic activity of the ethanol-inducible cytochrome P450 (CYP2E1) in human fetal liver and hepatocytes.
S P Carpenter, J M Lasker and J L Raucy

Molecular Pharmacology February 1996, 49 (2) 260-268;
You have access
Interleukin-1 alpha-induced modulation of topoisomerase I activity and DNA damage: implications in the mechanisms of synergy with camptothecins in vitro and in vivo.
Z Wang and B K Sinha

Molecular Pharmacology February 1996, 49 (2) 269-275;
You have access
Regulation of CYP4A expression in rat by dehydroepiandrosterone and thyroid hormone.
S J Webb, G H Xiao, T E Geoghegan and R A Prough

Molecular Pharmacology February 1996, 49 (2) 276-287;
You have access
Microtubule effects of welwistatin, a cyanobacterial indolinone that circumvents multiple drug resistance.
X Zhang and C D Smith

Molecular Pharmacology February 1996, 49 (2) 288-294;
You have access
Effects of expression of a mouse brain L-type calcium channel alpha 1 subunit on secretion from bovine adrenal chromaffin cells.
P F Wick, R E Westenbroek and R W Holz

Molecular Pharmacology February 1996, 49 (2) 295-302;
You have access
Trophic effect of exogenous nerve growth factor on rat striatal cholinergic neurons: comparison between intraparenchymal and intraventricular administration.
J L Venero, F Hefti and B Knusel

Molecular Pharmacology February 1996, 49 (2) 303-310;
You have access
Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.
E G Schuetz, W T Beck and J D Schuetz

Molecular Pharmacology February 1996, 49 (2) 311-318;
You have access
Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons.
J H Prehn, V P Bindokas, J Jordán, M F Galindo, G D Ghadge, R P Roos, L H Boise, C B Thompson, S Krajewski, J C Reed and R J Miller

Molecular Pharmacology February 1996, 49 (2) 319-328;
You have access
Oct-1 transcription factor is a negative regulator of rat CYP1A1 expression via an octamer sequence in its negative regulatory element.
K Sterling and E Bresnick

Molecular Pharmacology February 1996, 49 (2) 329-337;
You have access
Reserpine inhibits amphetamine action in ventral midbrain culture.
D Sulzer, C St Remy and S Rayport

Molecular Pharmacology February 1996, 49 (2) 338-342;
You have access
The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
B Rene, P Fosse, T Khelifa, A Jacquemin-Sablon and C Bailly

Molecular Pharmacology February 1996, 49 (2) 343-350;
You have access
Intracellular trafficking of the muscarinic acetylcholine receptor: importance of subtype and cell type.
J A Koenig and J M Edwardson

Molecular Pharmacology February 1996, 49 (2) 351-359;
You have access
Stimulation of Ca(2+)-dependent membrane currents in Xenopus oocytes by microinjection of pyrimidine nucleotide-glucose conjugates.
H Y Kim, D Thomas and M R Hanley

Molecular Pharmacology February 1996, 49 (2) 360-364;
You have access
Interaction of the COOH-terminal domain of the neurotensin receptor with a G protein does not control the phospholipase C activation but is involved in the agonist-induced internalization.
E Hermans, J N Octave and J M Maloteaux

Molecular Pharmacology February 1996, 49 (2) 365-372;
You have access
Dopamine D2L receptors stimulate Na+/K(+)-ATPase activity in murine LTK- cells.
I Yamaguchi, S F Walk, P A Jose and R A Felder

Molecular Pharmacology February 1996, 49 (2) 373-378;
You have access
Stimulatory regulation of the large-conductance, calcium-activated potassium channel by G proteins in bovine adrenal chromaffin cells.
K B Walsh, S P Wilson, K J Long and S C Lemon

Molecular Pharmacology February 1996, 49 (2) 379-386;